NFE2L1 and neoplasm: On one hand, this may result from NFE2L1 deficiency leading to ROS accumulation, which could activate dendritic cells (DCs) or enhance tumor antigen release, thereby promoting the recruitment and activation of CD4+ T cells and CD8+ T cells (marked by CD3e) [54, 55].